Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Strategic Transactions

Deanna has been with Strategic Transactions since 2000. In her role she researches, analyzes, and writes summaries of alliances, M&A, and fundraising activities among global biopharma and medtech companies. Deanna oversees the two Dealmaking columns and authors a Quarterly Statistics article, in addition to contributing content to In Vivo. Prior to joining Strategic Transactions, Deanna worked at Yale University, first in the Office of Medical Development as a gift support services coordinator assisting in fundraising activities and producing fund reports and donor gift acknowledgements. Later she worked at Yale's Department of Epidemiology and Public Health as a research assistant performing various tasks including editing the School of Public Health's website, identifying new funding prospects, providing grant support for the Dean, and preparing development materials and reports. Deanna holds a Bachelor of Science degree from the University of Vermont. In her spare time she enjoys boating and fishing with her family and friends.
Advertisement
Set Alert for Articles By Deanna Kamienski

Latest From Deanna Kamienski

Pacts In Medtech, July/August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in July and August 2017.

Deals Pacts in Medtech

Venture Funding Deals: Gene Editing Attracts Big Investors, Roivant Sets Financing Record

In the largest private biopharma round to date, Roivant raises $1.1bn to fund new subsidiaries. The next highest round in August was for gene-editing-focused Homology Medicines.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Tech Transfer Roundup: UM Ventures' Deal-Making Priority Is Flexibility

Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.

Deals StartUps and SMEs

Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers

A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.

StartUps and SMEs Financing
See All
Advertisement
UsernamePublicRestriction

Register